^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDKN2B mutation

    i
    Other names: CDKN2B, Cyclin Dependent Kinase Inhibitor 2B, Cyclin-Dependent Kinase Inhibitor 2B (P15, Inhibits CDK4), Cyclin-Dependent Kinase 4 Inhibitor B, Multiple Tumor Suppressor, P14-INK4b, P15-INK4b, MTS-2, MTS2, Cyclin-Dependent Kinases 4 And 6 Binding Protein, CDK Inhibitory Protein, P14_CDK Inhibitor, P15 CDK Inhibitor, CDK4B Inhibitor, P14_INK4B, P15_INK4B, P15INK4b, P15INK4B, CDK4I, INK4B, TP15, P15
    Entrez ID:
    1030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma. (PubMed, Front Oncol)
    PD-L1 high expression was similar between the 2 groups (mutated vs wild-type: 5.7% vs 6%,). GA associated with immune checkpoint inhibitors (ICPIs) response including PBRM1 (mutated vs wild-type: 0.7% vs 3.2%, p <0.0001) and MDM2 (mutated vs wild-type: 1.3% vs 4.4%, p <0.0001) were more likely to be seen in KRAS wild-type PDA.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • ATM (ATM serine/threonine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • MTAP (Methylthioadenosine Phosphorylase) • MDM2 (E3 ubiquitin protein ligase) • PBRM1 (Polybromo 1) • SMAD4 (SMAD family member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • TMB-H • PD-L1 overexpression • BRAF mutation • PIK3CA mutation • HER-2 mutation • ATM mutation • ARID1A mutation • FGFR2 mutation • KRAS wild-type • RAS wild-type • CDKN2A mutation • PBRM1 mutation • RB1 mutation • SMAD4 mutation • CDKN2B mutation • MDM2 mutation • MTAP mutation
    12ms
    Comprehensive Genome profile testing in head and neck cancer. (PubMed, Auris Nasus Larynx)
    Although there were no cases in which effective treatment was actually performed based on the results of CGP, many gene mutations have been detected and several gene mutations correlated with prognosis. Furthermore, TMB can be used as a biomarker to predict the therapeutic effects of immune checkpoint inhibitors in cases of SCC.
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    TP53 mutation • TMB-H • TMB-L • CDKN2A mutation • CDKN2B mutation
    1year
    The diagnostic significance of cerebrospinal fluid cytology and circulating tumor DNA in meningeal carcinomatosis. (PubMed, Front Neurol)
    CSF cytology is more sensitive than traditional imaging in the diagnosis of meningeal carcinomatosis and has significant advantages in the early screening and diagnosis of MC patients. CSF ctDNA can be used as a complementary diagnostic method to negative results of CSF cytology and MRI, and CSF ctDNA can be used as an important method for liquid biopsy of patients with MC, which has important clinical significance in revealing the possible molecular mechanisms and drug treatment targets of meningeal metastasis of LUAD.
    Journal • Circulating tumor DNA • Cytology
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • WT1 (WT1 Transcription Factor) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    EGFR mutation • MET amplification • CDKN2A mutation • MET mutation • CDKN2B mutation • WT1 mutation • SETD2 mutation
    over1year
    Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. (PubMed, Sci Rep)
    In advanced setting, in the IDH1m group, the presence of KRAS/NRAS and TP53 mutations negatively impact PFS, whereas the presence of TP53 and PIK3CA mutations negatively impact OS; in the IDH1wt group, only the presence of MTAP mutation negatively impact PFS, whereas the presence of TP53 mutation negatively impact OS. We highlighted several molecular differences with distinct prognostic implications between IDH1m and IDH1wt patients.
    Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CCND1 (Cyclin D1) • MTAP (Methylthioadenosine Phosphorylase) • PBRM1 (Polybromo 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH2 (Notch 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • RAD21 (RAD21 Cohesin Complex Component)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • PIK3CA mutation • IDH1 mutation • ATM mutation • FGFR2 mutation • CDKN2A mutation • PBRM1 mutation • CDKN2B mutation • IDH wild-type • MTAP mutation • NBN mutation
    |
    FoundationOne® CDx
    over1year
    IDH1 IN INTRAHEPATIC CHOLANGIOCARCINOMA: A COMPARATIVE GENOMIC ANALYSIS AND CLINICAL IMPACT (ILCA 2022)
    We highlighted several molecular differences with distinct prognostic implications between IDH1m and IDH1wt patients.
    Clinical • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CCND1 (Cyclin D1) • MTAP (Methylthioadenosine Phosphorylase) • PBRM1 (Polybromo 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH2 (Notch 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • RAD21 (RAD21 Cohesin Complex Component)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • PIK3CA mutation • IDH1 mutation • ATM mutation • FGFR2 mutation • CDKN2A mutation • PBRM1 mutation • CDKN2B mutation • IDH wild-type • MTAP mutation • NBN mutation
    |
    FoundationOne® CDx
    almost3years
    Mutational landscape of thymic epithelial tumors in a Chinese population: insights into potential clinical implications. (PubMed, Gland Surg)
    Our study provided a comprehensive genetic alteration view on the largest Chinese cohort of TETs to date. The results identified different genomic mutational profiles of Ts, TCs, and TNETs, and analyzed potential druggable biomarkers with clinical implications in Chinese TET patients, which provided the evidence for precision medicine of rare TET patients.
    Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    PD-L1 expression • TP53 mutation • CDKN2A mutation • CDKN2B mutation
    over3years
    [VIRTUAL] TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. (ASCO-GU 2021)
    The presence of a TERTp mutation was an independent predictor of improved OS in a cohort of aUC pts treated with ICI. Other common mutations and clinical variables were not associated with OS on a multivariable analysis. These findings are hypothesis-generating and prospective validation is needed.
    Clinical • Checkpoint inhibition • IO biomarker
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • TERT (Telomerase Reverse Transcriptase) • ALB (Albumin)
    |
    CDKN2B mutation